The argument about whether the malaria vaccine works is effectively over in Nigeria. Kebbi settled it.

Cases in the state fell from 49.0 per cent in 2021 to 18.4 per cent in 2025. In the areas the programme actually covered, prevalence went from 13.6 per cent to 1.7 per cent. Fever admissions dropped. That is not a marginal result requiring careful statistical framing. That is a disease being pushed back.

So the interesting question is no longer clinical. It is administrative, and considerably less exciting.

Four doses is a hard ask

The R21 schedule requires doses at five, six and seven months and a booster at fifteen. Five separate contacts with a health system, spread across ten months, in a country where a caregiver may be travelling an hour each way with other children at home.

Nigerian immunisation data has always shown attrition across multi-dose courses. The first dose is comparatively easy. The fourth is where programmes are won or lost.

Delivering through routine immunisation rather than a vertical campaign was the right call, because it means these contacts already exist in the calendar. But it also means the vaccine inherits every weakness of the routine system it rides on.

What to watch

Bauchi and Ondo have now joined Bayelsa and Kebbi. The number worth tracking as the programme widens is not prevalence — that will follow — but completion. Specifically, what share of children who receive dose one receive the fifteen-month booster.

Health workers in the pilot states reported a real improvement in caregiver awareness. If that travels with the programme, the rest is manageable. If it does not, Nigeria will have bought a very good vaccine and delivered three-quarters of it.

Reporting by The Guardian Nigeria. This summary was written by the TalkNaijaMedia desk.